Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I, dose-escalation, open-label clinical trial determining the safety and
tolerability of adding Pitavastatin to Venetoclax in subjects with chronic lymphocytic
leukemia (CLL) or acute myeloid leukemia (AML). These are subjects who are newly diagnosed
subjects with AML who are ineligible for intensive induction chemotherapy,
relapsed/refractory CLL or newly diagnosed CLL.